What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple Muhammad Ali Khalid Wed, July 15, 2026 at 5:43 PM GMT+2 2 min read LXEO Lexeo Therapeutics Inc. (NASDAQ: LXEO ) is one of the 10 best stocks under $10 that could triple . On June 15, Lexeo Therapeutics Inc.

(NASDAQ:LXEO) disclosed that it has finalized the critical trial protocol of SUNRISE-FA 2. The company also finalized the statistical analysis plan meant to offer clinical evidence for submission of a Biologics License Application to the U. S.

FDA. Pressmaster/Shutterstock. com The company highlighted that this submission is for the gene-based therapy candidate, LX2006, under the 2028 approval pathway.

Lexeo's Chief Medical Officer, Narinder Bhalla, M. D. , labeled it as a major stride that involves the completion of a critical study design for SUNRISE-FA 2.

He believes that it sets a path to assess LX2006 in Friedreich's ataxia cardiomyopathy. He further stated: "Patients living with FA, particularly those with cardiac involvement, have a significant unmet need for new treatment options and remain at the center of our efforts. This progress brings us one step closer to delivering a potential new therapy, and we remain focused on execution as we work to initiate the pivotal study and enroll the first patient by the end of the month.

" Later on June 25, JPMorgan reduced its target price for the stock from $12 to $9, which still yields an adjusted upside potential of over 92%. The firm reiterated an Overweight rating on the stock, based on a revised model that incorporates the company's latest updates. Lexeo Therapeutics Inc.

(NASDAQ:LXEO) is a clinical-stage company that develops genetic medicines to treat genetic disorders. It is developing medicines which include an AAVrh10-based therapy known as LX2006, used for treating Friedreich's ataxia associated with cardiomyopathy, and LX2020, which is developed to cure the heart muscles through gene delivery. While we acknowledge the potential of LXEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.

If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the   best short-term AI stock . READ NEXT:  33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years . Disclosure: None.

Follow Insider Monkey on Google News .